Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Target Lowered at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target lowered by equities researchers at Royal Bank Of Canada to $1.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 119.78% from the stock’s current price.

EYPT has been the subject of a number of other research reports. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Cantor Fitzgerald cut Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, August 17th. JPMorgan Chase & Co. restated an “underweight” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Chardan Capital cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target for the company. in a research report on Tuesday, August 18th. Finally, Mizuho restated a “neutral” rating and issued a $0.50 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals presently has an average rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Trading Up 3.4%

EYPT stock traded up $0.02 during trading on Tuesday, reaching $0.46. The stock had a trading volume of 21,784,316 shares, compared to its average volume of 3,148,209. Eyepoint Pharmaceuticals has a 52 week low of $0.40 and a 52 week high of $19.11. The stock’s 50 day moving average is $4.77 and its two-hundred day moving average is $10.30. The firm has a market cap of $39.23 million, a PE ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. On average, research analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors have recently made changes to their positions in EYPT. Cyndeo Wealth Partners LLC grew its holdings in Eyepoint Pharmaceuticals by 46.8% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock valued at $116,000 after buying an additional 11,329 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at approximately $161,000. Integrated Wealth Concepts LLC bought a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at approximately $72,000. Squarepoint Ops LLC lifted its stake in shares of Eyepoint Pharmaceuticals by 22.3% in the 2nd quarter. Squarepoint Ops LLC now owns 98,002 shares of the company’s stock valued at $1,401,000 after purchasing an additional 17,883 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 16.4% in the 2nd quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock valued at $468,000 after purchasing an additional 4,613 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada set a $1.00 price target, implying substantial potential upside from recent levels, while assigning a “sector perform” rating. However, the target was lowered, limiting the bullish significance. Tickerreport analyst update
• Neutral Sentiment: Mizuho reaffirmed its “neutral” rating and set a $0.50 price target, only modestly above the recent share price. HC Wainwright also reaffirmed its “neutral” rating. Tickerreport analyst update
• Neutral Sentiment: Unusual options activity saw investors purchase 7,885 call options, 69% above typical daily volume. This may indicate speculative interest but does not confirm a fundamental recovery.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. Shares have lost nearly 80% following the results, severely damaging confidence in the company’s lead program. LUCIA trial results
• Negative Sentiment: EyePoint plans to cut 53% of its workforce and halt wet-AMD clinical trials early, redirecting resources toward DURAVYU development in diabetic macular edema. The move should reduce expenses but highlights the scale of the clinical setback. EyePoint strategic prioritization
• Negative Sentiment: Guggenheim downgraded EYPT to “neutral,” while Jefferies cut its rating from “buy” to “hold” and set a $1.00 target. JPMorgan reaffirmed an “underweight” rating, reinforcing cautious analyst sentiment.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations related to the LUCIA results, adding legal and reputational risk for shareholders. EyePoint investigation notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.